Drug Trial Radar · NCT01150331
Study of Antiepileptic Drug in Generalised Convulsive Status Epilepticus
Last checked: Nov 20, 2026Latest source record: Jan 15, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
203
Actual
Start
Jul 2009
Primary completion
May 2013
Study completion Oct 2013
Sponsor
- Lead sponsor
- Assistance Publique - Hôpitaux de ParisAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- Collaborators
- URC-CIC Paris Descartes Necker Cochin
- First posted
- Jun 24, 2010
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double (participant, investigator)
- Primary purpose
- Treatment
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Compare the efficiency of the association, first line, the intravenous levetiracetam and the intravenous clonazepam, in that of a monotherapy of clonazepam intravenous in the pre-hospital treatment of tonicoclonic generalised status epilepticus.
Conditions
- Status; Epilepticus, Tonic-clonic
Interventions
Levetiracetam/ClonazepamDrug
Association of two anti-epileptic drugs in first line
Clonazepam/Placebo levetiracetam IVDrug
Association of placebo to an active comparator (clonazepam)
Primary outcomes
What the sponsor says the trial is designed to measure.
- Patient's percentage having stopped convulsing in the 15 minutes following the injection. The stop of the crisis is defined as the stop of all epileptic movements (myoclonic, clonic or tonic)Time frame: 15 minutes
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Necker Hospital
Paris, France
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.